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Abstract
Background: In 2000, the United States Food and Drug Administration approved Crotalidae Polyvalent
Immune Fab (Ovine) (hereafter, FabAV), "for the management of patients with minimal to moderate North
American Crotalid envenomation." Because whole-IgG pit viper antivenom is no longer available in the
United States, FabAV is currently the only specific treatment option available to United States clinicians
treating snakebite victims of any severity. No clinical trial data are available concerning the effectiveness
of FabAV for treatment of severe snakebite, but several published articles describe its use in this setting.
Methods: We performed a comprehensive review of the English-language medical literature to identify
all publications (1996 to July, 2008) containing data about the administration of FabAV. Two trained
reviewers separately extracted case-level data concerning the administration of FabAV to patients with
severe envenomation by North American crotaline snakes to a standardized form. Descriptive statistics
were used. In addition, we hand-searched the US National Poison Data System reports for the years 2000–
2006 to identify and describe any reports of death that occurred after FabAV administration.
Results: The literature review found 147 unique publications regarding FabAV. Twenty-four evaluable
cases of severe human envenomation treated with FabAV were identified in 19 publications. Seven cases
were described in five cohort studies, and 17 cases were described in 14 single patient case reports or
non-cohort case series. Sixty-five specific severe venom effects were reported in these 24 patients, of
which 50 effects (77%) improved or resolved after FabAV therapy. Initial control of all severe venom
effects was achieved in 12 patients (50%). The rate at which initial control was achieved was significantly
higher among patients reported in the cohort series than in the case series and non-cohort reports (100%
vs. 29%, P = 0.005). The median dose of FabAV used to obtain initial control was 6 vials (range: 4 – 18
vials). Nine patients had severe venom effects that persisted despite FabAV therapy. Recurrent and/or
delayed-onset severe defibrination syndrome occurred in 12 patients, most of whom did not receive
recommended maintenance FabAV dosing. No patient developed systemic bleeding.
Conclusion: In this structured literature review, FabAV appears to be effective in the management of
severe crotaline snake envenomation. Incomplete response to therapy, recurrence of venom effects, and
delayed-onset venom effects were reported in case reports, but not reported in cohort studies.
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Background
Each year, envenomation by pit viper snakes (Family
Viperidae, subfamily Crotalinae, genera Crotalus, Agkistro-
don, and Sistrurus) causes at least 2,700 people to seek hos-
pital treatment in the United States. About half of these
patients receive antivenom[1]. In October 2000, the
United States Food and Drug Administration (US FDA)
approved a Fab antivenom product for crotaline snake-
bite. Compared with equine-derived whole-IgG
antivenom, Crotalidae Polyvalent Immune Fab (Ovine)
(CroFab™, Protherics, Nashville, TN; hereafter, FabAV) is
thought to convey a reduced risk of acute and delayed-
type hypersensitivity reactions[2].
The US FDA approved FabAV based on two clinical trials,
both of which excluded patients with severe envenoma-
tion.[3-5] The reason for this exclusion was equipoise: at
the time the trials were conducted (1993–96), treating
life-threatening venom effects with investigational
antivenom in lieu of a proven standard therapy was con-
sidered unethical. As a result of the trial design, the US
FDA approved FabAV, "for the management of patients
with minimal or moderate North American crotalid
envenomation"[3].
Wyeth Pharmaceuticals announced in 2001 that it would
cease production of equine antivenom[6]. It appears that
the last lot of equine antivenom expired in April, 2007,
and no other antivenom has been approved for treating
crotaline snakebite[7]. Therefore, at the present time,
there is no approved antivenom therapy for severe crota-
line snakebite available in the United States.
Available data suggest that FabAV is being widely used to
treat severe envenomations. The 2006 report of the Amer-
ican Association of Poison Control Centers' National Poi-
son Data System (NPDS) lists 2,768 victims of crotaline
snake bite treated in a health care facility, of whom five
died, 1,528 had moderate to severe toxicity, and 1,239
had minimal or no clinical effects[1]. FabAV was admin-
istered to 1,359 patients during this period. In addition,
several cohort studies and many case reports have
described the use of FabAV to treat snake bite victims of all
severities.
We analyzed the English language medical literature to
characterize the reported response to FabAV therapy of
patients suffering severe crotaline envenomation.
Methods
We searched PubMed, Ovid MEDLINE, and EMBASE to
identify all published articles containing primary data
about North American crotalid envenomations treated
with FabAV. All searches were performed on July 28,
2008, using the search strategy listed in Table 1. All article
types were considered, including prospective clinical tri-
als, cohort and non-cohort case series, single case reports,
review articles, editorials, commentaries, published
abstracts, and letters-to-the-editor. Citation lists from the
three databases were imported into a ProCite database
(ProCite® version 5.0 for Windows, ISI ResearchSoft, Phil-
adelphia, PA, USA), and duplicate articles were removed.
We then performed an internal search to deselect articles
outside the scope of the search. The terms searched were
rat(s), mouse, mice, rabbit(s), cellular, in vivo, and in vitro.
A single medical toxicologist (EJL) then reviewed each
title and abstract. Articles judged to have no likelihood of
containing data about FabAV administration for North
American crotalid envenomations (e.g. reports that clearly
Table 1: Search terms
Database PubMed and Ovid Medline EMBASE
Search Terms MeSH headings:
• Crotalid Venoms
 /po (poisoning),
 /to (toxicity)
• Snake Venoms
 /po (poisoning),
 /to (toxicity)
• Snake Bites
 /dt (drug therapy)
 /th (therapy)
• Viperidae
• Agkistrodon
• Crotalus
'Crotalid venoms' AND (intoxication OR toxicity)
'Snake venoms' AND (intoxication OR toxicity)
'Snake bites' AND ('drug therapy' OR therapy)
Viperidae
Agkistrodon
Keywords:
• CroFab
• Crotaline immune Fab
FabAV
Crotalus
Crotaline immune Fab
FabAV
All searches were limited to English language, human, and dates of January 1, 1999 – July 28, 2008, inclusive.BMC Emergency Medicine 2009, 9:13 http://www.biomedcentral.com/1471-227X/9/13
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referred only to the treatment of African, Asian, or Austral-
ian snakebite) were excluded from further review.
Two supplemental sources complimented the computer-
ized literature search. Our article list was cross-referenced
with the topic-specific article files of Protherics, Inc, the
manufacturer of FabAV. The authors also searched the
bibliographies of all included articles, major textbooks in
emergency medicine and medical toxicology, and our
institutional article files for additional primary source
materials. These supplemental searches yielded some
publications prior to 1999.
Two board-certified medical toxicologists with experience
in the management of snakebite (EJL, THS) independ-
ently reviewed the full-text version of each article, identi-
fied all cases meeting the a priori definition of severe
envenomation (see below), and extracted case-level data
to a standardized form. This form consisted of two pages
for data concerning hypersensitivity reactions (collected
for a separate manuscript), one page for summary data
about any severe envenomation cases, and one additional
page for each severely envenomated patient reported.
Training on the abstraction step consisted of one hour of
instruction, followed by focused review of eleven practice
abstractions. The reviewers were not blinded to the intent
of the study. Data were entered into a Microsoft Access
database (Microsoft Access 2003®, Microsoft Corporation,
Redmond, WA, 2003) and double verified to ensure accu-
racy of data entry. Disagreement between the abstractors
was identified and resolved by consensus.
Included cases were reviewed to identify duplicate publi-
cation; where necessary, study authors were contacted to
determine if cases reported in different publications were
one and the same.
Data were analyzed using SAS (v. 9.1, SAS Institute, Cary,
NC). Descriptive statistics were used; confidence intervals
were not presented due to small sample sizes.
The definition of "severe" envenomation was that used in
the US FDA-approved prescribing information for FabAV
(Table 2). This standard definition contains several areas
of ambiguity, which were resolved a priori as follows:
The standard definition of local tissue effects classifies,
"swelling, pain, or ecchymosis involving less than a full
extremity," as "moderate," and, "swelling, pain or ecchy-
mosis involving more than an entire extremity," as
"severe." We included cases involving swelling, pain, or
ecchymosis involving exactly an entire extremity in the
"severe" group.
The standard definition of neurotoxicity classifies, "oral
paresthesias or unusual tastes," as "moderate," but has no
criteria for severe neurotoxicity. We considered severe
muscle weakness, difficulty speaking or swallowing, and
fasciculations remote from the bite site (sometimes a sign
of impending paralysis) to be signs of severe neurotoxic-
ity.
The phrase, "coagulation parameters are abnormal, with
serious bleeding or severe threat of bleeding," in the
standard definition required more precise definition.
Using published criteria, we considered "severe threat of
bleeding" to be present if the platelet count was less than
50,000 cells/mm3, if the fibrinogen was less than 50 mg/
dl (1.5 micromol/L), or if the international normalized
ratio (INR) or protime ratio were > 5.0[8] If protime was
reported without INR or normal range data, a protime >
50 seconds was considered to represent severe threat of
bleeding.
Table 2: Definitions of Envenomation Severity from the FabAV Prescribing Information[3]
Envenomation Category Definition
Minimal Swelling, pain, and ecchymosis limited to the immediate bite site;
Systemic signs and symptoms absent;
Coagulation parameters normal with no clinical evidence of bleeding.
Moderate Swelling, pain, and ecchymosis involving less than a full extremity or, if bite was sustained on the trunk, head or neck, 
extending less than 50 cm;
Systemic signs and symptoms may be present but not life threatening, including but not limited to nausea, vomiting, 
oral paresthesia or unusual tastes, mild hypotension (systolic blood pressure >90 mmHg), mild tachycardia (heart 
rate <150), and tachypnea;
Coagulation parameters may be abnormal, but no clinical evidence of bleeding present. Minor hematuria, gum 
bleeding and nosebleeds are allowed if they are not considered severe in the investigator's judgment.
Severe Swelling, pain, and ecchymosis involving more than an entire extremity or threatening the airway;
Systemic signs and symptoms are markedly abnormal, including severe alteration of mental status, severe 
hypotension, severe tachycardia, tachypnea, or respiratory insufficiency;
Coagulation parameters are abnormal, with serious bleeding or severe threat of bleeding.BMC Emergency Medicine 2009, 9:13 http://www.biomedcentral.com/1471-227X/9/13
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The standard definition does not specify a time point at
which severity is assessed. In order to mirror clinical prac-
tice, we graded the severity of envenomation based on the
initial presentation, i.e. the patient's clinical condition
during the first six hours after presentation for care. Cases
that were of minimal or moderate severity on initial pres-
entation, but that developed one or more features of
severe envenomation many hours or days later, were
counted as "minimal" or "moderate" based on the sever-
ity of the initial presentation.
In some cases, authors reported clinical manifestations
such as, "severe tachycardia," or, "hypotension," without
reporting numeric values. We counted these cases as,
"severe," if the author of the report described them as,
"severe."
The Snakebite Severity Score (SSS) is a validated tool for
assessing crotaline snake envenomation[9]. A SSS ≥ 7 is
generally considered to represent severe envenomation.
Although clinicians' global assessment of severity was
used to determine eligibility in the FabAV premarketing
trials, serial calculations of SSS were made in all patients
as the primary efficacy outcome of the premarketing trials
and at least one other report[4,5,10] Although the SSS is a
composite measure of severity, rather than a unique
venom effect, serial calculations of SSS were the only case-
level data presented about response to treatment in some
reports[4,5,10]. Therefore, when data were available, we
calculated the SSS for each case reported and included
those with a SSS ≥ 7 in the "severe" group.
In this report, we defined "initial control" of a specific
venom effect, a priori, as cessation of progression of local
tissue effects (pain and swelling), and as complete resolu-
tion of systemic effects (hypotension, neurotoxicity, and
medically important bleeding). In accordance with previ-
ous research, initial control of coagulopathy was defined
as definite improvement in coagulopathy or platelet
count tests, as appropriate, combined with the absence of
systemic bleeding[5,8,11-13]. "Initial control of the
envenomation syndrome" was defined a priori as simulta-
neous initial control of all specific venom effects experi-
enced by that particular patient.
After initial control of the envenomation syndrome is
achieved, the manufacturer of FabAV recommends
administration of 2-vial doses of FabAV, given at 6, 12,
and 18 hours ("maintenance therapy"), in order to pre-
vent recurrent or delayed onset venom effects[3,5]. We
scored a patient as having received maintenance therapy if
the patient received at least three doses of FabAV, each
consisting of two or more vials, within a 24-hour period
after initial control was reached.
Annual reports of the American Association of Poison
Control Centers' NPDS, and its predecessor, the Toxic
Exposure Surveillance System (TESS), contain robust sta-
tistical data about poisonings in general, and brief (< 100
word) case abstracts about fatal poison exposures.
Because they do not focus on snakebites, NPDS/TESS
reports were expected neither to be identified by the
search strategy, nor to contain sufficient detail to be
included in the main analysis. Nonetheless, they remain a
relevant, important source of peer-reviewed data. There-
fore, we hand-searched the 2000–2006 annual reports for
any reported fatalities that occurred after FabAV adminis-
tration[1,14-19].
Results
Article and subject identification
The search strategy identified 147 unique publications
regarding FabAV. The article selection process is depicted
in Figure 1. A total of 22 articles contained at least one
case of severe envenomation by a North American crota-
line snake treated with FabAV. These articles describe 30
apparently-unique cases of severe envenomation. From
this group, five cases did not contain sufficient data about
the clinical course after FabAV administration to judge
whether the manifestations of severe envenomation
responded to therapy, and one case was determined to be
included in two different series; these cases were therefore
excluded[10,20-24]. The remaining 24 cases from 19 pub-
lished reports are presented in Table 3[4,10,13,20,22,25-
38].
Five cohort studies and fourteen non-cohort studies were
identified. Two of the cohort studies collected data pro-
spectively, two collected data retrospectively, and one
used both prospective and retrospective data collection.
All of the non-cohort studies were of retrospective design.
Seven severely envenomated patients were reported in the
cohort studies, and 17 severely envenomated patients
were described in the non-cohort studies.
Initial response to FabAV therapy
Sixty-five specific severe venom effects were reported in
these 24 patients. The initial response to FabAV treatment
for these specific severe venom effects was: improved/
resolved, 50 effects (77%); no improvement, 11 effects
(17%); not reported, 4 effects (6%). All of the 22 specific
venom effects (100%) experienced by the seven patients
in the cohort studies improved after FabAV administra-
tion. In contrast, of the 43 specific venom effects experi-
enced by the patients in the non-cohort studies, 28 effects
improved or resolved (65%), 11 effects did not improve
(26%), and the response of 4 effects were not reported
(9%).BMC Emergency Medicine 2009, 9:13 http://www.biomedcentral.com/1471-227X/9/13
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Article identification and selection process Figure 1
Article identification and selection process. This information is also presented as an attached file.BMC Emergency Medicine 2009, 9:13 http://www.biomedcentral.com/1471-227X/9/13
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Table 3: Published cases of severe envenomation treated with FabAV
Publication Patient Identifying 
Information
Severe venom effects Was Initial Control of this 
Venom Effect Achieved?
Vials of FabAV for Initial 
Control
Cohort Studies
Prospective Data Collection
Bush 2002[10] Patient 13§ Altered mental status Yes 6
Hypotension Yes
Tachycardia Yes
Neurotoxicity Yes
SSS ≥ 7Y e s
Patient 14 Limb swelling Yes 6
Limb pain Yes
Hypotension Yes
Tachycardia Yes
SSS ≥ 7Y e s
Dart 1997[4] Patient 10 SSS ≥ 7Y e s 8
Platelet count < 50,000/
mm3
Yes
Fibrinogen < 50 mg/dl* Yes
Retrospective Data Collection
Lavonas 2004[25] 12-year-old Male Compartment syndrome Yes 4
Ruha 2002[13] Patient 1 Limb swelling Yes 18
Limb pain Yes
Protime > 50 sec Yes
Fibrinogen < 50 mg/dl* Yes
Platelet count < 50,000/
mm3
Yes
Mixed Prospective + Retrospective Data Collection
Offerman 2002[20] First coagulopathy patient† Fibrinogen < 50 mg/dl* Yes NR
Second coagulopathy 
patient†
Fibrinogen < 50 mg/dl* Yes NR
Platelet count < 50,000/
mm3
Yes
Non-Cohort Studies
Audi 2006[26] 80-year-old Female Altered mental status NR 6
Hypotension Yes
SSS ≥ 7Y e s
Platelet count < 50,000/
mm3
Yes
Camilleri 2005[27] 40-year-old Male Limb swelling Yes N/A
Limb pain NR
Bleeding No
Clark 1997[22] Case 1 Neurotoxicity Yes 12
Case 3 Neurotoxicity Yes 6
Fazelat 2008[28] 24-year-old Male SSS ≥ 7Y e s 1 0
Platelet count < 50,000/
mm3
YesBMC Emergency Medicine 2009, 9:13 http://www.biomedcentral.com/1471-227X/9/13
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Bleeding No
Gold 2004[29] 38-year-old Male Platelet count < 50,000/
mm3
No N/A
Horn 2007[30] 8-year-old Male Compartment syndrome No N/A
Lintner 2006[31] 2-year-old Male Limb swelling Yes 12
Platelet count < 50,000/
mm3
Yes
Miller 2002[32] Case 1 Limb swelling NR NR
Platelet count < 50,000/
mm3
Yes
Morgan 2006[33] 14-year-old Male Airway swelling Yes NR
Altered mental status Yes
Hypotension Yes
Need for intubation Yes
Bleeding Yes
SSS ≥ 7Y e s
INR > 5.0 Yes
Odeleye 2004[34] Case 1 Platelet count < 50,000/
mm3
No N/A
Case 2 Airway swelling Yes N/A
Need for intubation Yes
INR > 5.0 Yes
Platelet count < 50,000/
mm3
No
Offerman 2003[35] 42-year-old Male Limb swelling Yes 16
Limb pain Yes
Bleeding NR
Platelet count < 50,000/
mm3
Yes
Richardson 2007[36] Case 1 Need for intubation No N/A
Neurotoxicity No
Case 2 Neurotoxicity No N/A
SSS ≥ 7Y e s
Platelet count < 50,000/
mm3
Yes
Seifert 1997[37] 53-year-old Female Platelet count < 50,000/
mm3
Yes 6
Wasserberger 2006[38] 46-year-old Male Limb swelling No N/A
Limb pain No
Platelet count < 50,000/
mm3
Yes
© This patient was also patient 6 in the Offerman, 2002 case series[20]
† Drs. Bush and Offerman have confirmed that these patients and patients 13 and 14 in the Bush series are not the same subjects.
SSS = Snakebite Severity Score(Dart 96)
INR = International Normalized Ratio
NR = Not reported
N/A = Not applicable (initial control not obtained)
* Fibrinogen < 1.5 micromol/L
Table 3: Published cases of severe envenomation treated with FabAV (Continued)BMC Emergency Medicine 2009, 9:13 http://www.biomedcentral.com/1471-227X/9/13
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Initial control of the envenomation syndrome was
achieved in 12 patients (50%), not achieved in 9 patients
(38%), and not fully reported in 3 patients (13%). All
seven (100%) of the severely envenomated patients in the
cohort studies achieved initial control. Once again, the
response to initial therapy was not as good in the patients
reported in non-cohort studies. Among these 17 patients,
initial control of the envenomation syndrome was
achieved in 5 patients (29%), not achieved in 9 patients
(53%), and incompletely documented in 3 patients
(18%). The median dose of FabAV used to achieve initial
control of the envenomation syndrome in these 12
patients was 6 vials (range: 4 – 18 vials).
Persistent severe venom effects
One or more persistent severe venom effects were
reported in 0/7 patients reported in cohort studies (0%),
and in 9/17 patients in non-cohort reports (53%). These
cases are summarized in Table 4[27-30,34,36,38]. These
effects consisted of limb swelling, limb pain, soft tissue
bleeding, thrombocytopenia, neurotoxicity, or compart-
ment syndrome. Response to therapy was not reported for
four patients, summarized in Table 5[26,27,32,35].
Recurrence or delayed onset of severe venom effects
Recurrence or delayed-onset of at least one severe venom
effect was reported in 12 patients, including 3/7 patients
(43%) in the cohort studies, described in Table
6[4,10,13,27,28,31,32,34-38]. Maintenance therapy was
administered to two patients (17%), not administered to
9 patients (75%), and not documented for one patient
(8%). With one exception (recurrent limb pain and swell-
ing), all cases of recurrence or delayed onset of severe
venom effects involved defibrination (with or without
prothrombin time elevation) and/or thrombocytopenia,
and were clinically occult. Although these events were
judged a priori to represent "a severe threat of bleeding,"
none of the 11 patients (0%) with recurrent or delayed-
onset hematologic venom effects developed bleeding.
Permanent sequelae of envenomation
Few publications assessed and reported long-term out-
comes. Therefore, the available data are inadequate to
describe the long term outcomes after crotaline snakebite
treated with FabAV. No published manuscripts described
death following FabAV administration were identified in
the literature search.
Reports to the US National Poison Data System
The TESS/NPDS data include 21 deaths due to snakebite
reported to participating US poison control centers from
2000 – 2006[1,14-19]. Of these, five patients received
FabAV prior to death; two additional patients received
unspecified antivenom. These cases are summarized in
Table 7. Five patients presented in extremis and died of cer-
Table 4: Specific severe venom effects that persisted after FabAV administration
Publication Patient Identifying Information Persistent Severe Venom Effects Total Vials of FabAV
Cohort Studies (any design)
No cases
Non-Cohort Studies
Camilleri 2005[27] 40-year-old Male Bleeding 32
Fazelat 2008[28] 24-year-old Male Bleeding 26
Gold 2004[29] 38-year-old Male Platelet count < 50,000/mm3 46
Horn 2007[30] 8-year-old Male Compartment syndrome 10 (5 pre-operative)
Odeleye 2004[34] Case 1 Platelet count < 50,000/mm3 22
Case 2 Platelet count < 50,000/mm3 19
Richardson 2007[36] Case 1 Need for intubation 22
Neurotoxicity
Case 2 Neurotoxicity 10
Wasserberger 2006[38] 46-year-old Male Limb swelling
Limb pain
20BMC Emergency Medicine 2009, 9:13 http://www.biomedcentral.com/1471-227X/9/13
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ebral anoxia and/or multisystem organ failure; the other
two patients died from complications of substance abuse.
Discussion
Physicians in the United States treating victims bitten by
rattlesnakes, cottonmouth and copperhead snakes, and
pygmy rattlesnakes no longer have access to an antivenom
that is licensed and approved to treat severely envenom-
ated victims. The previous standard therapy, whole IgG
antivenom, is no longer available; the currently-available
antivenom, FabAV, was tested and approved only for use
in mildly and moderately envenomated patients. Those
patients with severe envenomation – hypotension, severe
hematologic effects, and/or severe limb findings – are
clinical "orphans." Data from the American Association of
Poison Control Centers suggest that, when faced with the
choice of off-label administration of FabAV or supportive
care only, treating physicians most often choose to
administer FabAV to severely envenomated patients[39].
It is difficult to conceive of a placebo-controlled trial of
FabAV in severe snakebite; to our knowledge, no such
study has been conducted.
A significant body of published literature describes the
overall clinical experience with FabAV; this study identi-
fied 147 relevant articles, of which 19 articles provided
case-level data about severely envenomated patients
treated with FabAV.
Out of approximately ten published cohort studies of
FabAV-treated patients, we were able to identify seven
patients from five reports who met our a priori definition
of severe envenomation. All seven of these patients dem-
onstrated good initial response to FabAV therapy.
Severe snakebite is sometimes associated with the need
for intubation, either due to airway edema or as part of
supportive care of a patient in shock. Our review found
three cases of severely envenomated patients who
required intubation. One case involved a patient who was
intubated for venom-induced periglottic edema, received
FabAV, and was successfully extubated the next day[34]. A
second case involved a patient who developed multisys-
tem organ failure after deliberate intravenous injection of
rattlesnake venom in a suicide attempt. The indication for
his intubation, which occurred prior to FabAV therapy,
was profound shock and gastrointestinal hemorrhage.
These problems responded quickly to FabAV therapy; the
patient successfully self-extubated on the third day of hos-
pitalization[33]. We judged both these cases to demon-
strate successful treatment of the venom effect, "need for
intubation," with FabAV. The third case involved a patient
who was intubated due to progressive neurotoxicity due
to envenomation by an unknown rattlesnake. Administra-
tion of FabAV failed to prevent the need for intubation,
and significant neurotoxicity progressed even after aggres-
sive FabAV therapy[36].
Recurrence and delayed onset of severe venom effects are
a known complication of snakebite, whether treated with
FabAV or whole-IgG antivenom[5,40,41]. Cases involving
both severe and initially-minor envenomation have been
previously reported[41]. Three of the seven patients
reported in the cohort studies developed recurrence phe-
nomena. Two of these cases involved recurrent defibrina-
tion syndrome without bleeding; neither patient received
maintenance FabAV therapy. Maintenance therapy has
been shown in a randomized controlled trial to prevent
early recurrence of local tissue venom effects. Use of main-
tenance therapy to prevent recurrent coagulopathy is
based on strong pharmacokinetic arguments[5,12,37,42].
The third patient developed recurrent limb pain and
swelling despite maintenance therapy.
Table 5: Specific severe venom for which response to therapy was not documented
Publication Patient Identifying Information Severe Venom Effects Total Vials of FabAV
Cohort Studies (any design)
No cases
Non-Cohort Studies
Audi 2006[26] 80-year-old Female Altered mental status 14
Camilleri 2005[27] 40-year-old Male Limb pain 32
Miller 2002[32] Case 1 Limb swelling 22
Offerman 2003[35] 42-year-old Male Bleeding 48BMC Emergency Medicine 2009, 9:13 http://www.biomedcentral.com/1471-227X/9/13
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Table 6: Recurrence or delayed onset of severe venom effects
Publication Patient Identifying 
Information
Vials of FabAV for 
Initial Control
Maintenance 
Therapy 
Administered?
Recurrent Severe 
Venom Effects
Delayed Onset 
Severe Venom 
Effects
Cohort Studies
Prospective Data Collection
Bush 2002[10] Patient 14 6 Yes Limb swelling
Limb pain
None
Dart 1997[4] Patient 10 8 No Fibrinogen < 50 mg/dl None
Retrospective Data Collection
Ruha 2002[13] Patient 1 18 No Protime > 50 sec None
Fibrinogen < 50 mg/dl
Mixed Prospective/Retrospective Data Collection
No cases
Non-Cohort Studies
Camilleri 2005[27] 40-year-old Male N/A No None Platelet count < 
50,000/mm3
INR >5
Fibrinogen < 50 mg/dl
Fazelat 2008[28] 24-year-old Male 10 Yes Platelet count < 
50,000/mm3
None
Lintner 2006[31] 2-year-old Male 12 No Platelet count < 
50,000/mm3
None
Miller 2002[32] Case 1 NR No None Fibrinogen < 50 mg/dl
Odeleye 2004[34] Case 2 N/A No INR > 5.0 None
Offerman 2003[35] 42-year-old Male 16 NR Platelet count < 
50,000/mm3
None
Richardson 2007[36] Case 1 N/A No None Fibrinogen < 50 mg/dl
Seifert 1997[37] 53-year-old Female 6 No Platelet count < 
50,000/mm3
None
Wasserberger 
2006[38]
46-year-old Male N/A No Platelet count < 
50,000/mm3
None
NR = Not reported
N/A = Not applicable (initial control not obtained)BMC Emergency Medicine 2009, 9:13 http://www.biomedcentral.com/1471-227X/9/13
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Unfavourable outcomes, including severe venom effects
that were refractory to the FabAV doses given, delayed-
onset severe venom effects, and recurrence phenomena,
were all reported more commonly in case reports and
other non-cohort studies than in cohort studies. The dif-
ference was statistically significant (P = 0.005 for initial
control, Fisher's Exact test). This is as expected; the presen-
tation of novel results ("originality factor") increases the
likelihood that a report will be accepted for presentation
at a scientific meeting, and that it will subsequently be
published as a full-length manuscript[43].
It is clear from these reports that, in some patients, defibri-
nation and/or thrombocytopenia do not respond to large
doses of FabAV. However, based on the observation that
no reports describe medically significant bleeding that
began after FabAV administration, the risk of bleeding in
this situation is probably low. Subsequent to this struc-
tured literature review, a case report of fatal cerebral hem-
orrhage associated with recurrent defibrination in a
FabAV-treated patient has been reported[44]. The authors
of this report could find no other cases of significant spon-
taneous bleeding in 34 published cases of recurrent coag-
ulopathy. A large cohort study of FabAV-treated patients,
followed to resolution with detailed biochemical charac-
terization including venom antigenemia, would be valua-
ble to address this important question. Until that time,
the recommendations made by Yip continue to represent
the best available guidance in this area, with the caveat
that, beyond a certain point, administration of additional
Table 7: Reports of death after FabAV administration reported to the US National Poison Data System, 2000–2006
Annual Report Year Case Number Clinical Summary
Patients Treated with FabAV
2001 55 A 17-year-old girl presented after apparent intravascular envenomation by an unknown snake with 
features of anaphylaxis to venom. Within minutes, she was hypotensive, profoundly hypoxic, developed 
pulmonary edema, and had a seizure. Treatment included intubation with ventilator support, dopamine, 
and FabAV (dose not reported). She never developed local tissue effects or coagulopathy. Despite 
maximal therapy, she died five days after envenomation.
2002 69 A 43-year-old man presented with severe hypotension after a rattlesnake bite. He remained 
hypotensive despite fluids, dopamine, epinephrine, diphenhydramine, steroids, and 26 vials of whole-
IgG antivenom. Disseminated intravascular coagulopathy developed. He then received six vials of 
FabAV, after which his blood pressure improved such that vasopressors were discontinued. He 
developed epistaxis and oral mucosal bleeding that was treated with 7 additional vials of whole-IgG 
antivenom and transfusions of platelets, fresh frozen plasma, and cryoprecipitate (response not 
reported). He developed renal failure, and ultimately died of multi-system organ failure.
2003 424 A 33-year-old man received FabAV for an apparently uncomplicated rattlesnake envenomation. He was 
discharged from the hospital 24 hours later with only minimal symptoms, and was given a prescription 
for oxycodone with acetaminophen. He died of an apparent overdose of oxycodone that night.
2004 52 A 52-year-old man presented with a forearm compartment syndrome due to a copperhead snakebite. 
He received FabAV and underwent a dermotomy of his finger and a fasciotomy of his arm. 
Subsequently, he developed severe alcohol withdrawal, which was treated with diazepam, haloperidol, 
and fentanyl, which led to respiratory arrest, aspiration, and acute respiratory distress syndrome. 
Medical care was withdrawn, and the patient died.
2004 53 A 55-year-old man presented with severe hypotension and coma from apparent intravascular 
envenomation from a rattlesnake. FabAV therapy and aggressive resuscitation were not initiated for 
several hours. The patient developed renal failure, disseminated intravascular coagulopathy, and 
circulatory collapse, and died seven hours after envenomation.
Patients Treated with Unspecified Antivenom
2001 56 A 30-year-old man presented comatose after rattlesnake envenomation. On presentation, he was 
found to have coagulopathy, thrombocytopenia, and a subarachnoid hemorrhage. He received "10 to 
20 vials" of unspecified antivenom, but died after withdrawal of life support.
2005 57 A 32-year-old man presented to the emergency department in respiratory arrest due to anaphylaxis 
from a rattlesnake bite. He received unspecified antivenom, and subsequently died of anoxic 
encephalopathy.
Includes data from the Toxic Exposures Surveillance System (predecessor to the NPDS), 2000–2005.BMC Emergency Medicine 2009, 9:13 http://www.biomedcentral.com/1471-227X/9/13
Page 12 of 14
(page number not for citation purposes)
FabAV to patients with refractory hemostatic dysfunction
is unlikely to be beneficial[8].
The recommended dosing of FabAV is 4- to 6-vial aliq-
uots, repeated as needed until the desired clinical effect is
achieved. In the premarketing studies of mild and moder-
ately envenomated patients, the median dose of FabAV
used to achieve initial control of the envenomation syn-
drome was 6 vials (range: 3 to 12 vials)[4,5]. In this review
of severely envenomated patients, initial control of severe
venom effects was achieved after a median dose of 6 vials
(range: 4 to 18 vials) was administered. Some patients
received extraordinary doses in response to persistent or
recurrent severe venom effects; whether patients benefited
from doses in excess of 18 vials, excluding maintenance
therapy, is unclear.
The NPDS contains information about 15,917 crotaline
snake envenomations treated in a health care facility from
2000 to 2006; 21 of these patients (0.13%) died. Five
fatality reports describe death that occurred after FabAV
administration; another two patients received unspecified
antivenom prior to death. No deaths appear to be caused
by an adverse reaction to FabAV. Although it is difficult to
make broad conclusions based on the sparse descriptions
in these reports, the lack of any clear cases of treatment-
failure associated death is reassuring. The fact that the fatal
case reported by Kitchens and Eskin did not appear in the
NPDS reports underscores one weakness of US poison-
center based data, which rely on voluntary reporting[44].
In addition to issues surrounding retrospective data col-
lection and publication bias, this report is limited by the
lack of a comparison group. Published reports of severely
envenomated North American crotalid victims managed
without antivenom are extremely rare; therefore, it is dif-
ficult to differentiate the response to FabAV therapy from
the natural history of untreated snakebite.
Because of the number of patients reported in cohort
series is small, we cannot estimate the true rate of treat-
ment failures, death, and other uncommon but important
adverse events in the larger population of severely enven-
omated patients treated with FabAV.
No study reported in this series examined long-term out-
comes.
One prior study, reported only in abstract form, has eval-
uated the use of FabAV in treatment of severe crotalid
envenomation[45]. In that retrospective review of poison
center cases, 9.3% of crotalid envenomations were judged
to be severe. Initial control was achieved in 57% of severe
cases, using a mean dose of 10.5 vials of FabAV.
As with any review, the conclusions of this report are lim-
ited by the available literature. To our knowledge, the larg-
est cohort study of Crotaline snake bite victims treated
with FabAV reported 93 cases[46]. A much larger, multi-
center cohort study would be extremely useful to better
define the answers to unresolved management issues.
Conclusion
In this integrative review of the published literature, treat-
ment of severely-envenomated crotalid snake victims with
FabAV was generally associated with good short-term out-
comes. Persistent, recurrent, or delayed-onset venom
effects, particularly thrombocytopenia and defibrination,
were observed in several patients, but no patient devel-
oped bleeding complications after receiving FabAV.
FabAV therapy was well-tolerated. FabAV therapy appears
to be appropriate in the management of severely enveno-
mated crotalid snake victims.
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